Bicara Therapeutics/$BCAX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bicara Therapeutics
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
Ticker
$BCAX
Sector
Primary listing
Employees
103
Headquarters
Website
BCAX Metrics
BasicAdvanced
$1.5bn
-
-$2.52
-
-
Price and volume
Market cap
$1.5bn
52-week high
$24.25
52-week low
$7.80
Average daily volume
575k
Financial strength
Current ratio
14.579
Quick ratio
14.329
Long term debt to equity
0.148
Total debt to equity
0.426
Profitability
EBITDA (TTM)
-155.499
Effective tax rate (TTM)
-0.16%
Management effectiveness
Return on assets (TTM)
-20.67%
Return on equity (TTM)
-30.88%
Valuation
Price to book
3.1
Price to tangible book (TTM)
3.1
Price to free cash flow (TTM)
-11.659
Free cash flow yield (TTM)
-8.58%
Free cash flow per share (TTM)
-1.959
Growth
Earnings per share change (TTM)
-37.64%
3-year earnings per share growth (CAGR)
-69.42%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bicara Therapeutics stock?
Bicara Therapeutics (BCAX) has a market cap of $1.5B as of April 29, 2026.
What is the P/E ratio for Bicara Therapeutics stock?
The price to earnings (P/E) ratio for Bicara Therapeutics (BCAX) stock is 0 as of April 29, 2026.
Does Bicara Therapeutics stock pay dividends?
No, Bicara Therapeutics (BCAX) stock does not pay dividends to its shareholders as of April 29, 2026.
When is the next Bicara Therapeutics dividend payment date?
Bicara Therapeutics (BCAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Bicara Therapeutics?
Bicara Therapeutics (BCAX) does not currently have a Beta indicator.